Millennium seeks to update Velcade labeling with overall survival data
This article was originally published in Scrip
Executive Summary
Takeda's oncology unit Millennium Pharmaceutical submitted a supplemental application to the US FDA to add overall survival data after a five-year follow-up to the product labeling for Velcade (bortezomib).